All > Multiple Myeloma

CC-93269 for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Multiple MyelomaCC-93269 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for people with multiple myeloma that has come back or does not respond to treatment.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
LMY-920 dose escalation
1
Summer STRIPES
1
Gemcitabine and Capecitabine

Study Objectives

4 Primary · 16 Secondary · Reporting Duration: Up to 60 months

Up to 48 months
Pharmacokinetics - accumulation index of CC-93269
Up to 60 months
Adverse Events (AEs)
Dose Limiting Toxicity (DLT)
Duration of Response
Evaluate measures of tumor sensitivity/ resistance to CC-93269
Maximum Tolerated Dose (MTD)
Non-Tolerated Dose (NTD)
Overall Response Rate (ORR)
Overall Survival
Pharmacokinetics - AUC
Pharmacokinetics - CL
Pharmacokinetics - Cmax
Pharmacokinetics - Cmin
Pharmacokinetics - Vss
Pharmacokinetics - accumulation index of alnuctamab
Pharmacokinetics - t1/2
Pharmacokinetics - tmax
Presence and frequency of anti-drug antibodies (ADA)
Progression Free Survival
Time to Response

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
LMY-920 dose escalation
1
Summer STRIPES
2
Gemcitabine and Capecitabine

Trial Design

1 Treatment Group

Administration of CC-93269
1 of 1

Experimental Treatment

220 Total Participants · 1 Treatment Group

Primary Treatment: CC-93269 · No Placebo Group · Phase 1

Administration of CC-93269
Drug
Experimental Group · 1 Intervention: CC-93269 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

CelgeneLead Sponsor
625 Previous Clinical Trials
172,950 Total Patients Enrolled
139 Trials studying Multiple Myeloma
39,100 Patients Enrolled for Multiple Myeloma
Michael R Burgess, MD, PhDStudy DirectorCelgene
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,407 Previous Clinical Trials
3,308,947 Total Patients Enrolled
62 Trials studying Multiple Myeloma
21,513 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top